

1 **Surveillance of Vermont wildlife in 2021-2022 reveals no detected SARS-CoV-2 viral RNA**

2 Hannah W. Despres¹, Margaret G. Mills², Madaline M. Schmidt¹, Jolene Gov², Yael Perez²,
3 Mars Jindrich², Allison M. L. Crawford², Warren T. Kohl², Elias Rosenblatt⁷, Hannah C.
4 Kubinski¹, Benjamin C. Simmons³, Miles C. Nippes³, Anne J. Goldenberg³, Kristina E. Murtha³,
5 Samantha Nicoloro³, Mia J. Harris³, Avery C. Feeley³, Taylor K. Gelinis³, Maeve K. Cronin³,
6 Robert S. Frederick³, Matthew Thomas³, Meaghan E. Johnson³, James Murphy³, Elle B.
7 Lenzini³, Peter A. Carr Jr. ³, Danielle H. Berger³, Soham P. Mehta³, Christopher J. Floreani³,
8 Amelia C. Koval³, Aleah L. Young³, Jess H. Fish³, Jack Wallace³, Ella Chaney³, Grace Ushay³,
9 Rebecca S. Ross³, Erin M. Vostal³, Maya C. Thisner³, Kyliegh E. Gonet³, Owen C. Deane³, Kari
10 R. Pelletiere³, Vegas C. Rockafeller³, Madeline Waterman³, Tyler W. Barry³, Catriona C.
11 Goering³, Sarah D. Shipman³, Allie C. Shiers³, Claire E. Reilly³, Alanna M. Duff³, David J.
12 Shirley⁴, Keith R. Jerome^{2,5}, Ailyn C. Pérez-Osorio², Alexander L. Greninger^{2,5}, Nick Fortin⁶,
13 Brittany A. Mosher^{7,*}, Emily A. Bruce^{1,*}

14

15 **Affiliations:**

16 ¹Department of Microbiology and Molecular Genetics, Robert Larner, M.D. College of Medicine,
17 University of Vermont, Burlington VT, 05405, USA.

18 ²Virology Division, Department of Laboratory Medicine and Pathology, University of Washington,
19 Seattle WA 98195, USA.

20 ³Wildlife and Fisheries Society, University of Vermont, Wildlife Society Chapter

21 ⁴Faraday, Inc. Department of Engineering. Burlington VT, 05405.

22 ⁵Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle WA 98109,
23 USA.

24 ⁶Vermont Agency of Natural Resources, Fish & Wildlife Department, Rutland, VT 05701

25 ⁷Rubenstein School of Environment and Natural Resources, University of Vermont, 81 Carrigan
26 Dr Burlington, VT 05405, USA

27

28 ***Address correspondence to:** Emily.bruce@med.uvm.edu (EAB), Brittany.mosher@uvm.edu
29 (BAM)

30

31 **Abstract**

32 Previous studies have documented natural infections of SARS-CoV-2 in various
33 domestic and wild animals. More recently, studies have been published noting the susceptibility
34 of members of the Cervidae family, and infections in both wild and captive cervid populations. In
35 this study, we investigated the presence of SARS-CoV-2 in mammalian wildlife within the state
36 of Vermont. 739 nasal or throat samples were collected from wildlife throughout the state during
37 the 2021 and 2022 harvest season. Data was collected from red and gray foxes (*Vulpes vulpes*
38 and *Urocyon cinereoargenteus*, respectively), fishers (*Martes pennati*), river otters (*Lutra*
39 *canadensis*), coyotes (*Canis latrans*), bobcats (*Lynx rufus rufus*), black bears (*Ursus*
40 *americanus*), and white-tailed deer (*Odocoileus virginianus*). Samples were tested for the
41 presence of SARS-CoV-2 via quantitative RT-qPCR using the CDC N1/N2 primer set and/or the
42 WHO-E gene primer set. Our results indicate that no sampled wildlife were positive for SARS-
43 CoV-2. This finding is surprising, given that most published North America studies have found
44 SARS-CoV-2 within their deer populations. The absence of SARS-CoV-2 RNA in populations
45 sampled here may provide insights in to the various environmental and anthropogenic factors
46 that reduce spillover and spread in North American's wildlife populations.

47 **Introduction**

48 Severe acute respiratory syndrome associated coronavirus-2 (SARS-CoV-2), the virus
49 that causes COVID-19, is most recognized for its ability to easily transmit from person-to-
50 person. Recently, natural infections in a range of domestic and wild animals have also been
51 documented¹⁻⁴. With every new animal infected, the zoonotic potential of SARS-CoV-2
52 increases. Animal species that facilitate within-species transmission of SARS-CoV-2 are
53 possible new reservoirs of the virus, and this transmission could lead to evolutionary changes in
54 the virus that would pose a risk to humans upon reintroduction. In fact, this exact scenario
55 occurred during 2020, with SARS-CoV-2 infection documented in farmed minks^{5,6}. Notably, the

56 Netherlands reported five different outbreak events in 2020, resulting in over 50% of mink farms
57 having animals that tested positive for SARS-CoV-2. At over half of the farms with positive
58 animals, employees also tested positive for SARS-CoV-2. Sequencing data from both the mink
59 and humans suggests that both spillover, the transmission of disease from animals to humans,
60 and spillback, the transmission of disease from humans to animals, occurred several times
61 between these two populations⁶. Infected animals were detected in mink farms in multiple other
62 countries which led to the selective culling of animals at affected farms, as well as the culling of
63 all (>17 million) mink in Denmark, to reduce the risk of spillover^{7,8}.

64 Spillover, the transmission of disease from animal to human, and spill back, the
65 transmission of disease from animals back into people, are both thought to be relatively rare in
66 Vermont (VT). However, multiple recent studies in North America have shown that members of
67 the Cervidae family are susceptible to SARS-CoV-2. We hypothesized that SARS-CoV-2 might
68 be circulating in Vermont deer and wildlife, given the numerous reports of infections within wild
69 deer populations^{4,9-15}, and laboratory infections showing vertical¹⁶ and horizontal transmission¹⁷.
70 North American deer are of particular concern as they are common, interact with humans, and
71 are also domestically farmed. All three of these factors create opportunities for spillover and
72 spillback events. The 2021 estimate for Vermont's white-tailed deer population was
73 approximately 133,000¹⁸, which is about a 1:5 deer-to-person ratio within the state¹⁹. While
74 SARS-CoV-2 has been detected in wildlife in several US states and Canadian provinces, there
75 is currently no published data on the virus in wildlife in the state of Vermont.

76 In this study, we examined the prevalence of SARS-CoV-2 viral RNA in a variety of animals
77 native to Vermont via reverse transcription quantitative polymerase-chain reaction (RT-qPCR),
78 using two different primer sets specific to SARS-CoV-2. We sampled fur-bearing animals
79 including red and grey foxes (*Vulpes vulpes* and *Urocyon cinereoargenteus*, respectively), fishers
80 (*Martes pennati*), otters (*Lutra canadensis*), coyotes (*Canis latrans*), bobcats (*Lynx rufus*

81 *rufus*), and big-game animals including white-tailed deer (*Odocoileus virginianus*) and black
82 bears (*Ursus americanus*) over the 2021 and 2022 hunting seasons.

83 **Results**

84 Our SARS-CoV-2 surveillance effort covered the state of Vermont through the hunting and
85 trapping seasons of 2021 (Oct 2021-March 2022) and the hunting season of 2022 (Oct-Nov
86 2022). We prioritized white-tailed deer, given their prevalence, potential interaction with
87 humans, and our ability to collect high-quality samples for processing. In addition to white-tailed
88 deer, the 2021 season also included a variety of fur-bearing animals that are commonly trapped

89 in VT, including foxes, fishers, otters,
90 coyotes, and bobcats. In 2021, we sampled
91 17 white-tailed deer as well as 250 fur-
92 bearers (Table 1). However, most of our
93 white-tailed deer sampling occurred during
94 the 2022 season, where we were able to
95 sample 470 white-tailed deer as well as 2
96 black bears (Table 1). Sampled animals were
97 harvested across the state of Vermont,
98 generating samples from a broad geographic
99 range (Figure 1, Figure S1). At the
100 conclusion of the 2021 season, we extracted


Species	2021 Season	2022 Season
White-tailed Deer (<i>Odocoileus virginianus</i>)	17	470
Foxes (<i>Vulpes vulpes</i> & <i>Urocyon cinereoargenteus</i>)	19	0
Fishers (<i>Martes pennati</i>)	77	0
Otters (<i>Lutra canadensis</i>)	43	0
Coyotes (<i>Canis latrans</i>)	32	0
Bobcats (<i>Lynx rufus rufus</i>)	79	0
Black bears (<i>Ursus americanus</i>)	0	2

Table 1. Number of samples collected by species type for each season.

101 RNA from all collected samples and performed RT-qPCR using the Centers for Disease Control
102 and Prevention (CDC) SARS-CoV-2 N1 and N2 primer set for the structural nucleocapsid
103 protein²⁰ to test for the presence of viral RNA. We found no detectable SARS-CoV-2 RNA within
104 any sample from the 2021 season (n = 272). Positive control wells on each plate amplified as

105 expected, as did the internal control included in each sample extraction to confirm RNA integrity
106 and rule out PCR inhibition. (Dataset S1).

107 At the
108 conclusion of the deer
109 sampling period in
110 2022, we thawed all
111 collected samples,
112 divided each sample
113 into two aliquots (one
114 for RT-qPCR and one
115 for future viral
116 isolation), re-froze



117 samples at -80°C , and
118 performed RNA
119 extraction and RT-
120 qPCR as above for the

Figure 1. Geographic distribution of specimen harvest. Geographic distribution of wildlife sampled for SARS-CoV-2 in Vermont during the 2021 and 2022 hunting seasons is shown. Specimens are shown based on the reported town where the harvest occurred and colored according to the number of samples collected from each location. Graphs were generated using QGIS.

121 2021 season samples. Surprisingly, when we analyzed samples from the 2022 season ($n =$
122 472), we observed a positivity rate of 28.2% of samples positive for both the N1 and N2 primers
123 (133/472). The average cycle threshold (C_T) for these samples was 36.6 for N1 and 38.0 for N2
124 ($SD = 1.3$ and 1.4 , respectively). There were multiple additional samples positive by either the
125 N1 or N2 primer sets, but not by both (N1 only = 28 samples, N2 only = 56 samples) (Dataset
126 S1). The suddenly high number of positive samples, paired with the high average C_T values and
127 the lack of any samples with a $C_T < 30$ for N1 or $C_T < 33$ for N2 raised concerns that these initial
128 numbers from the 2022 season may have been the result of contamination. In the period
129 between processing the 2021 and 2022 samples, The University of Vermont's laboratory began

130 a separate project that involved *in vitro* expression of the SARS-CoV-2 nucleocapsid protein,
131 and thus a DNA construct containing the sequences recognized by the N1 and N2 primer sets
132 was newly present in the general laboratory environment.

133 Therefore, we set out to determine if the positive results seen with the N1/N2 primers
134 were authentic or the result of plasmid DNA contamination in the laboratory environment from
135 the University of Vermont during the sample aliquoting, before any sample analysis. First, we
136 performed environmental swabbing of commonly used items and surfaces within the laboratory,
137 including within the biosafety cabinet used to aliquot the wildlife specimens before RT-qPCR
138 testing, the pipettes used for aliquoting, the laboratory bench, and pipettes. We detected SARS-
139 CoV-2 N nucleic acids on all surface swabs with both the N1 and N2 primers with C_T s as low as
140 23.6 (Dataset S2). None of the negative controls for the RT-qPCR reaction amplified. To
141 determine if we were detecting RNA or DNA contamination, we next performed a quantitative
142 polymerase chain reaction (qPCR) in which the typical incubation for reverse transcription was
143 omitted, instead beginning directly with a 95°C step to deactivate RT and activate hot-start Taq.
144 The positive controls (remnant SARS-CoV-2 positive clinical specimen) included in these
145 experiments exhibited an average N1 C_T 5.4 ± 0.6 cycles higher in qPCR experiment than in RT-
146 qPCR, as expected for samples where the input material was RNA rather than DNA (Figure 2).
147 Two of the three positive controls were undetectable with the N2 primer set in qPCR
148 experiments; for the third, the N2 C_T was 1.8 cycles higher in qPCR experiment than in RT-
149 qPCR. In contrast, all laboratory sites sampled (except the biosafety cabinet floor, which had the
150 highest C_T originally) showed consistent C_T s between RT-qPCR and qPCR reactions (average
151 N1 C_T 0.3 ± 0.9 cycles higher in qPCR experiment than in RT-qPCR), suggesting that the surface
152 contamination consisted of DNA rather than RNA (Figure 2).

153 Next, we compared qPCR and RT-qPCR amplification on select deer specimens that
154 showed amplification with either the N1 or N2 primer sets (see Figure 2 for a subset and
155 Dataset S2 for

156 complete data). In
157 each case, we were
158 still able to detect
159 viral nucleic acids,
160 and as seen in the
161 surface swabs the
162 C_T s were consistent

163 between RT-qPCR
164 and qPCR reactions
165 (average N1 C_T
166 1.1 ± 1.4 cycles lower
167 in qPCR experiment
168 than in RT-qPCR).

169 This result indicated that the original N1/N2 results were most likely detecting DNA
170 contamination. The contamination likely occurred during the aliquoting step (after specimen
171 collection), and illustrates the great difficulty posed by performing RT-qPCR based surveillance
172 efforts in tandem with experiments that require the handling of plasmid DNA or PCR product
173 without a physically separate facility, as previously reported²¹⁻²⁴. Given the similar C_T values for
174 both the RT-qPCR and qPCR of laboratory surfaces and deer specimen samples, as well as the
175 presence of N gene plasmid DNA (and associated contamination) in the laboratory where the
176 samples were aliquoted, we concluded that the 2022 N1/N2 results were false positives.

177 To accurately detect the presence of SARS-CoV-2 viral RNA in the 2022 season
178 samples, we repeated our RT-qPCR analysis using a new and independent set of primers, this




Figure 2. Environmental Swabs Show Contamination of SARS-CoV-2 Nucleocapsid DNA in Laboratory Environment. Samples from residual clinical SARS-CoV-2 positive specimens (pos #1-3), laboratory surfaces and equipment used to process/aliquot field samples (BSC=Biosafety Cabinet) and a selection of deer that initially tested positive for SARS-CoV-2 nucleic acid with the N1 primer set were analyzed by RT-PCR (to detect either RNA or DNA) and PCR (to detect RNA). The difference in cycle threshold (C_T) between PCR and RT-PCR for each sample is shown. Positive control clinical samples shown in orange circles, environmental swabs shown in blue squares, deer samples shown in gray triangles.

179 time targeting the E gene²⁵ rather than N. There was no E gene plasmid DNA present in the
180 laboratory in which these samples were processed and aliquoted, and no E amplification
181 products were present at any point in the study. All 474 samples from the 2022 season were
182 undetectable by the E gene primer/probe set, indicating that there was no detectable SARS-
183 CoV-2 viral RNA in any Vermont wildlife surveilled during the 2021 or 2022 seasons (Dataset
184 S1).

185

186 **Discussion**

187 White-tailed deer can both successfully be infected with and transmit SARS-CoV-2. This
188 has been demonstrated by both laboratory studies^{16,17} and several reports of naturally infected
189 deer in multiple states and provinces within the United States and Canada^{4,9-15}. Since prior
190 surveillance studies have reported RT-qPCR positivity rates of upwards of 30% in nasal swabs⁴
191 and seropositivity rates of more than 40%^{12,26}, it was initially surprising that no animals within
192 the Vermont sample set were positive, especially during the 2022 season. However, recent
193 work from Diel et al. describing the spread of SARS-CoV-2 within deer in New York state during
194 the 2021 and 2022 seasons showed only sporadic positives during 2021 and a significant
195 increase (up to 20%) in the 2022 season¹⁵. Furthermore, the majority of positive cases were
196 detected in the western half of New York and near New York City, the farthest regions
197 geographically from the Vermont border¹⁴. A second study furthers this argument, revealing the
198 relatively low positivity rate of 1.2% within the Quebec province in Canada, directly north of
199 Vermont²⁷. Therefore, SARS-CoV-2 may be circulating in Vermont deer at a low level. To
200 assess our ability to detect this, we performed a power analysis to calculate the probability of
201 detecting one case of SARS-CoV-2 within our 472 samples from the 2022 deer season as a
202 function of underlying SARS-CoV-2 prevalence. If we were to repeat our surveillance efforts, we
203 would expect to find at least one positive sample 80% of the time if the underlying prevalence
204 were at least 0.34%; similarly, we have 95% power to detect from a population that was 0.64%

205 positive, and there is only a 1% chance of our sampling no positives if the population were
206 0.97% positive (Figure S2).

207 While it has not been established how SARS-CoV-2 is introduced into wild deer
208 populations, it seems likely that this occurs via human-to-deer transmission, deer-to-deer
209 transmission, or a combination of the two^{26,28}. Vermont may have multiple features that reduced
210 the risk of human-to-deer transmission so far in the COVID-19 pandemic. First, the state of
211 Vermont is sparsely populated in general, but especially in many of the places where deer are
212 hunted, therefore reducing the potential for human-deer interaction. Additionally, the number of
213 COVID-19 human infections within the state of Vermont was much lower than most other places

214 within the USA (including
215 neighboring states with
216 higher levels of SARS-
217 CoV-2 detected in deer)
218 during the period in which
219 we were conducting
220 surveillance (Figure 3,
221 Dataset S3).

222 Finally, Vermont
223 lacks an established deer
224 farm industry, with only
225 three farms reported in
226 2017²⁹, all which contain
227 cervid species other than
228 white-tailed deer since it is

229 illegal to have captive white-tailed deer in Vermont. This agricultural set-up decreases the number
230 and duration of direct contact between humans and cervids in the state. Transmission between




Figure 3. Case Counts and Prevalence of COVID-19 in Vermont and New York. Geographic distribution of COVID-19 cases (reported by the Vermont Department of Health and New York State Department of Health) during the surveillance period for the 2022 season (Oct 15th- Nov 15th 2022) at the county level. Raw case counts are shown on left and prevalence (case counts/county population) is shown on right (population counts are an estimate based on US Census 2022 data). Graphs were generated using QGIS.

231 farmed animals (such as mink) and farm employees that care for them has been well documented
232 for viruses including SARS-CoV-2 and is a plausible route for the initial introduction of SARS-
233 CoV-2 into deer populations as well³⁰. Texas, Pennsylvania, Indiana, Ohio, and Michigan alone
234 account for over 65% of deer farms within the United States²⁹ and several of these states have
235 also reported high rates of SARS-CoV-2 prevalence in captive and/or wild deer^{9,11–13,30}.

236 A limitation of this study is the lack of samples other than nasal swabs, such as
237 retropharyngeal lymph nodes or blood samples. Retropharyngeal lymph nodes (RPLNs) are
238 commonly collected as part of surveillance efforts for chronic wasting disease; however, VT only
239 conducts surveillance for this disease when warranted by clinical signs/symptoms currently, and
240 not on hunter harvested deer. A 2022 study from Ontario, Canada reported a 2.3% (5/213)
241 positivity in nasal swabs, compared to a 6% (17/298) positivity in retropharyngeal lymph nodes
242 within the white-tailed deer they sampled, potentially demonstrating the increased sensitivity of
243 RPLNs samples to detect SARS-CoV-2 in this species¹⁰. Since no blood samples or lymph
244 nodes were collected in this study, we were unable to perform serology experiments to detect
245 the presence of SARS-CoV-2 antibodies that would reveal SARS-CoV-2 disease history. The
246 results reported here only represent a lack of active infections in the animals surveilled at a
247 single discrete timepoint. While information into the natural history of SARS-CoV-2 infections in
248 wildlife during the 2022 season would be highly informative, the lack of standard collection of
249 blood samples at Vermont hunting check stations was logistically prohibitive for the acquisition
250 of these samples during the 2021-2022 hunting seasons.

251 While our findings that there does not appear to be widespread SARS-CoV-2 in Vermont
252 deer are reassuring at present, we do not expect this to continue indefinitely considering the
253 increasing cases detected in the wildlife of neighboring regions. Surveillance efforts to help
254 detect the transmission and adaptation of SARS-CoV-2 in wildlife should be established
255 throughout North America and should ideally prioritize species susceptible to infection. Ongoing
256 surveillance studies will be required to understand not only the status of SARS-CoV-2 in

257 Vermont wildlife populations, but also to understand the transmission and spread of the disease
258 over time. Efforts to monitor the prevalence and mutational changes in SARS-CoV-2 viral
259 genome are especially important within common and social species, such as white-tailed deer.
260 The human health implication of deer as a SARS-CoV-2 reservoir is a sincere concern and
261 warrants continued surveillance as a crucial measure in pandemic preparedness.

262

263 **Methods**

264 *Wildlife Specimen Procurement*

265 All samples were collected in collaboration with the Vermont Agency of Natural Resources,
266 Department of Fish & Wildlife. All white-tailed deer and bear samples were collected during the
267 Vermont hunting season. For the 2021 season, deer samples were collected on the opening
268 weekend of rifle season (November 12th, 2022). For the 2022 season, samples were collected
269 on youth weekend (Oct 22-23rd, 2022) and the opening weekend of rifle season (November 12th-
270 13th, 2022). During these dates, samples were collected across the state of Vermont from
271 deceased animals brought to big game reporting stations by hunters.

272 For fur-bearing animals (i.e., foxes, otters, coyotes, bobcats, and fishers), whole-animal
273 carcass specimens were collected throughout the entirety of 2021 and stored at -20°C until
274 SARS-CoV-2 swab sample collection occurred in a batch-wise fashion during February-March
275 2022. Most whole-animal specimens were collected between October 2021 and March 2022
276 and therefore stored for only a few months (details for individual specimens available in Dataset
277 S1).

278 Nasal swabs were collected by inserting a dry, sterile swab (Copan #164KS01)
279 approximately 1 inch into each nasal cavity of the specimen and making five passes around the
280 interior of the nostril, ensuring even contact with the wall of the cavity. If the nasal cavity was
281 inaccessible, throat swabs were taken by inserting the swab as far back into the throat as
282 possible and making five passes around the entire circumference (denoted in Dataset S1).

283 Samples were stored in 3mL of phosphate-buffered saline (Gibco #10010023) on ice until
284 returning to the laboratory where they were transferred to -80°C until further use.

285

286 *Environmental Swabbing for Laboratory Plasmid Contamination*

287 Environmental contamination samples were collected by rubbing the surface of interest
288 with a dry, sterile swab (Copan #164KS01) for approximately 10 seconds, rolling the swab
289 during this time to ensure maximal surface contact. Samples were stored in 1mL of phosphate-
290 buffered saline (Gibco #10010023) and stored at -80°C until nucleic acid extraction and
291 amplification could occur.

292

293 *Nucleic Acid Extraction & Amplification*

294 All 2022 season samples were thawed once and aliquoted at the University of Vermont
295 between sample collection and extraction. All further processing and testing of swabs took place
296 in a Clinical Laboratory Improvement Amendments (CLIA)- and College of American
297 Pathologists (CAP)-certified facility at the University of Washington Virology Laboratory.

298 Total nucleic acids (TNA) were extracted using Roche MagNA Pure 96 instruments as
299 previously described³¹, with 200µL of swab liquid extracted and eluted into 50µL. Each
300 extraction plate included a positive control (pooled SARS-CoV-2-positive clinical remnants) and
301 a negative control (cells derived from a HeLa cell line). All amplifications used AgPath ID One-
302 Step RT-PCR enzyme and master mix (Life Technologies, ThermoFisher, Cat. #4387424M) and
303 10µL of TNA per reaction and were carried out on ABI 7500 thermocyclers. In addition to the
304 positive and negative controls from each extraction, each amplification plate contained a No-
305 Template negative control (NTC; water). One of two primer/probe sets was used in all reactions:
306 WHO-E²⁵; or multiplexed CDC N1 and N2³². RT-qPCR amplifications consisted of 10' at 48°C
307 (reverse transcription), 10' at 95°C (Reverse Transcriptase inactivation / polymerase hot-start),

308 and 40 cycles of 15" at 95°C and 45" at 60°C. qPCR amplifications used the same cycling
309 conditions but omitted the initial 10' at 48°C step. EXO RNA was added to all samples prior to
310 extraction, and EXO amplification was included in every RT-qPCR reaction as an internal
311 control to monitor for RNA degradation and PCR inhibition³².

312

313 *Data Availability*

314 All code, supplemental manuscript metadata, and supporting information can be found in
315 GitHub @emilybrucelab (<https://github.com/emilybrucelab>).

316

317 **Acknowledgements**

318 This study was supported by NIH grant P30GM118228-04 and UVM start-up funds (EAB) and
319 an American Heart Association predoctoral fellowship (HWD). We would like to acknowledge
320 the Vermont Agency of Natural Resources, Fish & Wildlife Department for allowing us to
321 participate in all their ongoing research efforts to collect these samples. We would also like to
322 thank the students of the Wildlife & Fisheries Club at the University of Vermont for helping
323 collect samples. Finally, a big thank you to all the Vermont hunters that were willing to
324 participate in our efforts.

325

326

327

328

329

330

331

332

333 Bibliography


- 334 1. McAloose D, Laverack M, Wang L, et al. From People to Panthera: Natural SARS-CoV-2
335 Infection in Tigers and Lions at the Bronx Zoo. *mBio*. 2020;11(5):e02220-20.
336 doi:10.1128/mBio.02220-20
- 337 2. Schulz C, Martina B, Mirolo M, et al. SARS-CoV-2–Specific Antibodies in Domestic Cats
338 during First COVID-19 Wave, Europe - Volume 27, Number 12—December 2021 -
339 Emerging Infectious Diseases journal - CDC. doi:10.3201/eid2712.211252
- 340 3. Sit THC, Brackman CJ, Ip SM, et al. Infection of dogs with SARS-CoV-2. *Nature*.
341 2020;586(7831):776-778. doi:10.1038/s41586-020-2334-5
- 342 4. Hale VL, Dennis PM, McBride DS, et al. SARS-CoV-2 infection in free-ranging white-tailed
343 deer. *Nature*. 2022;602(7897):481-486. doi:10.1038/s41586-021-04353-x
- 344 5. Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, et al. Transmission of SARS-CoV-2 on
345 mink farms between humans and mink and back to humans. *Science*. 2021;371(6525):172-
346 177. doi:10.1126/science.abe5901
- 347 6. Lu L, Sikkema RS, Velkers FC, et al. Adaptation, spread and transmission of SARS-CoV-2
348 in farmed minks and associated humans in the Netherlands. *Nat Commun*.
349 2021;12(1):6802. doi:10.1038/s41467-021-27096-9
- 350 7. Mutant coronaviruses found in mink spark massive culls and doom a Danish group's
351 research. Accessed March 10, 2023. [https://www.science.org/content/article/mutant-](https://www.science.org/content/article/mutant-coronaviruses-found-mink-spark-massive-culls-and-doom-danish-group-s-research)
352 [coronaviruses-found-mink-spark-massive-culls-and-doom-danish-group-s-research](https://www.science.org/content/article/mutant-coronaviruses-found-mink-spark-massive-culls-and-doom-danish-group-s-research)
- 353 8. Coronavirus: Denmark shaken by cull of millions of mink. *BBC News*.
354 <https://www.bbc.com/news/world-europe-54890229>. Published November 11, 2020.
355 Accessed March 10, 2023.
- 356 9. Kuchipudi SV, Surendran-Nair M, Ruden RM, et al. Multiple spillovers from humans and
357 onward transmission of SARS-CoV-2 in white-tailed deer. *Proc Natl Acad Sci*.
358 2022;119(6):e2121644119. doi:10.1073/pnas.2121644119
- 359 10. Pickering B, Lung O, Maguire F, et al. Divergent SARS-CoV-2 variant emerges in white-
360 tailed deer with deer-to-human transmission. *Nat Microbiol*. 2022;7(12):2011-2024.
361 doi:10.1038/s41564-022-01268-9
- 362 11. Marques AD, Sherrill-Mix S, Everett JK, et al. Multiple Introductions of SARS-CoV-2 Alpha
363 and Delta Variants into White-Tailed Deer in Pennsylvania. *mBio*. 2022;13(5):e02101-22.
364 doi:10.1128/mbio.02101-22
- 365 12. Chandler JC, Bevins SN, Ellis JW, et al. SARS-CoV-2 exposure in wild white-tailed deer
366 (*Odocoileus virginianus*). *Proc Natl Acad Sci*. 2021;118(47):e2114828118.
367 doi:10.1073/pnas.2114828118
- 368 13. Palermo PM, Orbegozo J, Watts DM, Morrill JC. SARS-CoV-2 Neutralizing Antibodies in
369 White-Tailed Deer from Texas. *Vector-Borne Zoonotic Dis*. 2022;22(1):62-64.
370 doi:10.1089/vbz.2021.0094

- 371 14. Vandegrift KJ, Yon M, Surendran Nair M, et al. SARS-CoV-2 Omicron (B.1.1.529) Infection
372 of Wild White-Tailed Deer in New York City. *Viruses*. 2022;14(12):2770.
373 doi:10.3390/v14122770
- 374 15. Caserta LC, Martins M, Butt SL, et al. White-tailed deer (*Odocoileus virginianus*) may serve
375 as a wildlife reservoir for nearly extinct SARS-CoV-2 variants of concern. *Proc Natl Acad*
376 *Sci*. 2023;120(6):e2215067120. doi:10.1073/pnas.2215067120
- 377 16. Cool K, Gaudreault NN, Morozov I, et al. Infection and transmission of ancestral SARS-
378 CoV-2 and its alpha variant in pregnant white-tailed deer. *Emerg Microbes Infect*.
379 2022;11(1):95-112. doi:10.1080/22221751.2021.2012528
- 380 17. Palmer MV, Martins M, Falkenberg S, et al. Susceptibility of White-Tailed Deer (*Odocoileus*
381 *virginianus*) to SARS-CoV-2. *J Virol*. 2021;95(11):e00083-21. doi:10.1128/JVI.00083-21
- 382 18. White-Tailed Deer FAQs | Vermont Fish & Wildlife Department. Accessed March 6, 2023.
383 [https://vtfishandwildlife.com/hunt/hunting-and-trapping-opportunities/white-tailed-deer/white-](https://vtfishandwildlife.com/hunt/hunting-and-trapping-opportunities/white-tailed-deer/white-tailed-deer-faqs)
384 [tailed-deer-faqs](https://vtfishandwildlife.com/hunt/hunting-and-trapping-opportunities/white-tailed-deer/white-tailed-deer-faqs)
- 385 19. U.S. Census Bureau QuickFacts: Vermont. Accessed March 6, 2023.
386 <https://www.census.gov/quickfacts/VT>
- 387 20. Centers for Disease Control and Prevention Division of Viral Diseases. CDC 2019-Novel
388 Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel. Atlanta: Centers for
389 Disease Control and Prevention; 2020.
- 390 21. Evans GE, Murdoch DR, Anderson TP, Potter HC, George PM, Chambers ST.
391 Contamination of Qiagen DNA Extraction Kits with *Legionella* DNA. *J Clin Microbiol*.
392 2003;41(7):3452-3453. doi:10.1128/JCM.41.7.3452-3453.2003
- 393 22. Koncan R, Valverde A, Morosini MI, et al. Learning from mistakes: Taq polymerase
394 contaminated with β -lactamase sequences results in false emergence of *Streptococcus*
395 *pneumoniae* containing TEM. *J Antimicrob Chemother*. 2007;60(3):702-703.
396 doi:10.1093/jac/dkm239
- 397 23. Montgomery TL, Paavola M, Bruce EA, Botten JW, Crothers JW, Kremmentsov DN.
398 Laboratory Worker Self-Contamination with Noninfectious SARS-CoV-2 DNA Can Result in
399 False-Positive Reverse Transcriptase PCR-Based Surveillance Testing. *J Clin Microbiol*.
400 2021;59(7):e00723-21. doi:10.1128/JCM.00723-21
- 401 24. Robinson-McCarthy LR, Mijalis AJ, Filsinger GT, et al. Laboratory-Generated DNA Can
402 Cause Anomalous Pathogen Diagnostic Test Results. *Microbiol Spectr*. 2021;9(2):e00313-
403 21. doi:10.1128/Spectrum.00313-21
- 404 25. Corman V, Bleicker T, Brünink S, et al. Diagnostic detection of 2019-nCoV by real-time RT-
405 PCR. Published online 2020:13.
- 406 26. Bevins SN, Chipman RB, Beckerman SF, et al. SARS-CoV-2 occurrence in white-tailed
407 deer throughout their range in the conterminous United States. Published online April 17,
408 2023:2023.04.14.533542. doi:10.1101/2023.04.14.533542

- 409 27. Kotwa JD, Massé A, Gagnier M, et al. First detection of SARS-CoV-2 infection in Canadian
410 wildlife identified in free-ranging white-tailed deer (*Odocoileus virginianus*) from southern
411 Québec, Canada. Published online January 21, 2022:2022.01.20.476458.
412 doi:10.1101/2022.01.20.476458
- 413 28. McBride D, Garushyants S, Franks J, et al. Accelerated evolution of SARS-CoV-2 in free-
414 ranging white-tailed deer. *Res Sq*. Published online February 16, 2023:rs.3.rs-2574993.
415 doi:10.21203/rs.3.rs-2574993/v1
- 416 29. List of Reports and Publications | 2017 Census of Agriculture | USDA/NASS. Accessed
417 February 20, 2023.
418 https://www.nass.usda.gov/Publications/AgCensus/2017/index.php#full_report
- 419 30. Roundy CM, Nunez CM, Thomas LF, et al. High Seroprevalence of SARS-CoV-2 in White-
420 Tailed Deer (*Odocoileus virginianus*) at One of Three Captive Cervid Facilities in Texas.
421 *Microbiol Spectr*. 2022;10(2):e00576-22. doi:10.1128/spectrum.00576-22
- 422 31. Bruce EA, Mills MG, Sampoleo R, et al. *Predicting Infectivity: Comparing Four PCR-Based*
423 *Assays to Detect Culturable SARS-CoV-2 in Clinical Samples.*; 2021:2021.07.14.21260544.
424 doi:10.1101/2021.07.14.21260544
- 425 32. Nalla AK, Casto AM, Huang MLW, et al. Comparative Performance of SARS-CoV-2
426 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit. *J Clin*
427 *Microbiol*. 58(6):e00557-20. doi:10.1128/JCM.00557-20


428

429 Supplemental Figures



Supplemental Figure 1. Geographic distribution of 2021 sample collection by species. Graphs generated using QGIS.

439



Supplemental Figure 2: Power to Detect a Given Prevalence. Using the binomial distribution for 472 trials (the number of deer samples collected in the 2022 hunting season), we calculated the probability of at least one success (SARS-CoV-2 detection) as a function of the unknown underlying SARS-CoV-2 prevalence (percent positivity).